Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

HR 528Sesión 2025-2026

Qué cambió entre versiones

7 párrafos cambiaron+382 palabras agregadas−396 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

See other bills

under the

same topic

PRINTER'SH0528R3413A03651 AJB:JMT 06/15/26 #90 A03651AMENDMENTS TO HOUSE RESOLUTION NO. 3413 THE528Sponsor: GENERALREPRESENTATIVE ASSEMBLYM. OF PENNSYLVANIAHOUSE RESOLUTIONBROWNPrinter's No.528 Session3413Amend Resolution, page 1, lines 1 through 19; pages 2 and 3, lines 1 through 30; page 4, lines 1 through 22; by striking out all of 2026said INTRODUCEDlines BYon COOPER,said BRIGGS,pages PASHINSKI,and STEELE,inserting STRUZZI, BRENNAN AND C. WILLIAMS, MAY 14, 2026 REFERRED TO COMMITTEE ON HEALTH, MAY 14, 2026 A RESOLUTIONDirectingDirecting the Joint State Government Commission to conduct a study on pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.WHEREAS, Pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), a subset of PANS, are considered immune-mediated disorders that may be triggered by many different infections, such asincluding streptococcal infections, whichand that may cause sudden and severe neuropsychiatric symptoms, including obsessive-compulsive behaviors, tics, anxiety, restricted eating, mood swings and cognitive deterioration; andWHEREAS, The American Academy of Pediatrics clinical report on PANS noted that PANS is difficult to diagnose due to the lack of disease-specific biomarkers, strong evidence for pathogenic causes or consensus on treatment; andWHEREAS, The American Academy of Pediatrics noted that the evidence base for PANS encompasses multiple subspecialties, including child and adolescent psychiatry, pediatric rheumatology, pediatric neurology, pediatric infectious diseases, pediatric immunology and developmental-behavioral pediatrics; andWHEREAS, The true lifetime prevalence of PANS and PANDAS is not known, and frequentdifficulty misdiagnosisin diagnosis makes it difficult to estimate the number of peopleindividuals affected; andWHEREAS, EffectiveSome providers believe that effective treatments for PANS and PANDAS, including psychiatric and behavioral interventions, antibiotics, anti-inflammatory therapies and intravenous immunoglobulin (IVIG), can lead to full recovery; ifandWHEREAS, administeredA promptlylimited butnumber of health care practitioners in this Commonwealth have specialized training in the diagnosis and treatment of PANS and PANDAS, which may create barriers to timely and appropriate care for affected patients oftenand experiencefamilies limited2026/90AJB/HR0528A03651 - or1 delayed access 12345678910111213141516171819-12345678910111213141516171819202122232425262728293031323334353637

to these treatments because of inconsistent insurance coverage and a shortage of knowledgeable health care providers; andWHEREAS, The Pennsylvania Rare Disease Advisory Council (PARDAC) serves as an advisory board to the General Assembly and other State and private agencies that provide services to or are charged with the care of individuals with rare diseases but has not yet issued specific resources or recommendations on PANS and PANDAS; andWHEREAS, A limited number of health care practitioners in this Commonwealth have specialized training in the diagnosis and treatment of PANS and PANDAS, which creates significant barriers to timely and appropriate care for affected patients and families across this Commonwealth; andWHEREAS, Patients affected by PANS and PANDAS are frequently misdiagnosed with primary psychiatric disorders such as obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, oppositional defiant disorder, Tourette's syndrome, autism spectrum disorder, avoidant or restrictive food intake disorder, anorexia, major depressive disorder, generalized anxiety disorder or bipolar disorder, which leads to delayed treatment and prolonged suffering; andWHEREAS, There are no State laws that mandate insurance coverage for PANS and PANDAS treatments, unlike 22 states that offer some insurance coverage and at least 15 states, including Illinois, Massachusetts, Virginia and California, that have enacted laws requiring coverage for diagnosis and therapies such as IVIG; andWHEREAS, A comprehensive study is necessary to address gaps in awareness, resources, insurance coverage, provider capacity and policy in order to better support affected patients and 20260HR0528PN3413 - 2 - 123456789101112131415161718192021222324252627282930

across this Commonwealth; andWHEREAS, Insurance coverage for PANS may not cover all preferred treatments; andWHEREAS, Twenty-two states offer some insurance coverage for PANS and PANDAS, and at least 15 states have enacted laws requiring coverage for diagnosis and therapies, including intravenous immunoglobulin; andWHEREAS, A comprehensive study is necessary to address gaps in awareness, resources, insurance coverage, provider capacity and policy in order to better support affected patients and families across this Commonwealth; therefore be itRESOLVED, That the House of Representatives direct the Joint State Government Commission to conduct a study on pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections in this Commonwealth; and be it furtherRESOLVED, That the Joint State Government Commission, in conducting the study, examine all of the following:(1) Which insurers, if any, currently cover offered treatments for PANS and PANDAS, including psychiatric and behavioral interventions, diagnostic tests, antibiotics, anti-inflammatory medications and immunomodulatory therapies, suchincluding asintravenous IVIGimmunoglobulin.(2) ExistingInsurance resourcescompany provideddecision by the Commonwealthmaking regarding coverage for treatments of PANS and PANDAS, including anythe initiatives,justification fundingfor orcoverage guidance from PARDACdecisions.(3) An estimate of the number of health care practitioners who treat PANS and PANDAS across this Commonwealth, including pediatricians, neurologists, rheumatologists, immunologists and psychiatrists with relevant expertise.(4) The mostestimated commonlength misdiagnosesof fortime PANSbetween the onset of symptoms and PANDASa and the impactdiagnosis of those misdiagnoses on patient outcomesPANS.(5) Legislative and policy actions taken by other states to address PANS and PANDAS, including insurance mandates, mandated provider education, awareness campaigns and advisory councils.(6) Recommendations for legislation or policy changes in this Commonwealth to improve appropriate diagnosis, treatment access, insurance coverage, provider education and support services for PANS and PANDAS.(7) Any other information that the Joint State 20260HR0528PN3413 Government Commission deems necessary for the completion of the study;and be it furtherRESOLVED, That the Joint State Government Commission, in carrying out the study, consult with Statewide medical organizations, including the Pennsylvania Medical Society and the Pennsylvania Chapter of the American Academy of Pediatrics, pediatric providers, including child and adolescent psychiatrists, pediatric rheumatologists, pediatric infectious 2026/90AJB/HR0528A03651 - 32 - 123456789101112131415161718192021222324252627282930123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051

Governmentdisease Commission deems necessary for the completion of the study;and be it furtherRESOLVEDexperts, Thatpediatric the Joint State Government Commissionimmunologists, indevelopmental-behavioral carrying out the study, consult with PARDAC, Statewide medical organizations, such as the Pennsylvania Medical Societypediatricians and thepediatric Pennsylvania Chapter of the American Academy of Pediatricsneurologists, national experts in PANS, including the Stanford Immune Behavioral Health/PANS Research Consortium at StanfordProgram, health insurers that operate in this Commonwealth, rare disease advocacy groups, such asincluding PANDAS/PANS Parents of Pennsylvania, the PANDAS Physicians Network and ASPIRE, the Alliance to Solve PANS and Immune-Related Encephalopathies, and health care access groups, such asincluding the Pennsylvania Health Access Network, to develop evidence-based recommendations for inclusion in the study report; and be it furtherRESOLVED, That the Joint State Government Commission issue a report of its findings and recommendations to the House of Representatives no later than 18 months after the adoption of this resolution; and be it furtherRESOLVED, That, upon issuance of the report required under this resolution, copies of thisthe resolutionreport be transmitted to the Department of Health, the Insurance Department and the organizations consulted in the study.20260HR0528PN3413 2026/90AJB/HR0528A03651 - 43 - 1234567891011121314151617181920212212345678910111213141516171819

Volver al texto completo